Results for trapjantati translation from Maltese to English

għalhekk, l-użu f’pazjenti trapjantati mhuwiex rakkomandat.
therefore, use in transplanted patients is not recommended.

prevenzjoni ta’ rifjut ta’ organi trapjantati (ciclosporin).
preventing rejection of transplanted organs (ciclosporin).

simulect jaħdem billi jwaqqaf ċelloli immuni li jattakaw organi trapjantati.
simulect works by stopping the immune cells that attack transplanted organs.

myclausen jintuża biex jipprevjeni lill-ġisem milli jirrifjuta kilwa, qalb jew fwied trapjantati.
myclausen is used to prevent the body from rejecting a transplanted kidney, heart or liver.

cellcept jintuża biex jevita milli l-ġisem ma jaċċettax kilwa, qalb jew fwied trapjantati.
cellcept is used to prevent the body from rejecting a transplanted kidney, heart or liver.

iċ-ċelloli trapjantati jattakkaw il-ġisem tiegħek (graft versus host disease)
the transplanted cells attack your body (graft versus host disease)

dawn iċ-ċelloli huma involuti f’li jagħrfu ċelloli ‘barranin’ u jirrifjutaw organi trapjantati.
these cells are involved in recognising ‘foreign’ cells and rejecting transplanted organs.

iċ-ċelloli trapjantati jattakkaw il-ġisem tiegħek (graft versus host disease) kumplikazzjonijiet tan-nifs
the graft attacks your body (graft versus host disease) respiratory complications

cellcept 1 g/ 5 ml trab għal suspensjoni orali jintuża biex ma jħallix il- ġisem tiegħek jiċħad kilwa, qalb jew fwied trapjantati.
cellcept 1 g/ 5 ml powder for oral suspension is used to prevent your body rejecting a transplanted kidney, heart or liver.

it- trattament b' advagraf għandu jiġi preskritt biss minn tobba li jkollhom esperjenza fil- ġestjoni ta 'pazjenti trapjantati.
treatment with advagraf should only be prescribed by doctors who have experience in the management of transplant patients.

cellcept trab għall- konċentrat għal soluzzjoni għall- infużjoni jintuża biex ma jħallix il- ġisem tiegħek jiċħad kilwa, jew fwied trapjantati.
cellcept 500 mg powder for concentrate for solution for infusion is used to prevent your body rejecting a transplanted kidney or liver.

dan inaqqas l-għadd ta’ limfoċiti-t attivati, u jnaqqas ir-riskju li l-organi trapjantati jiġu riġettati.
this reduces the number of activated t-lymphocytes, lowering the risk of the transplant being rejected.

dan jgħin liċ-ċelloli trapjantati biex jiġu ‘engrafted’ (meta jibdew jikbru u jipproduċu ċelloli tad-demm normali).
this helps the transplanted cells to ‘engraft’ (when they start to grow and produce normal blood cells).

il-kumitat għall-prodotti mediċinali għall-użu mill-bniedem (is-chmp) iddeċieda li l-benefiċċji ta’ simulect huma ikbar mir-riskji tiegħu għall-profilassi ta’ riġettar akut tal-organi trapjantati f’pazjenti adulti u tfal li jkunu għadhom kemm ħadu trapjant alloġeniku ta’ kilwa.
the committee for medicinal products for human use (chmp) decided that simulect’s benefits are greater than its risks for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation in adult and paediatric patients.